Survival analyses
SECONDARY
The secondary efficacy endpoint of 12 month survival was met. The 12 month overall survival was 52.7% (95% CI 40.1–69.2%) in the intent-to-treat population and 53.1% (95% CI 36.8–67.0%) in patients who received the declared dose of DNX-2401 (Fig. 